Collaborative relationships

Major Research and Development Interactions

Pharmagenesis, Inc. recognizes scientific collaborations as an essential part of its Research and Development and commercialization strategies. New collaborations are currently being developed. Several collaborative agreements were previously established.

Stanford University Medical School, Stanford, CA
Pharmagenesis, Inc. has two sponsored research agreements with Stanford involving the anti-cancer lead, PG490.  One Principle Investigator is seeking to determine the molecular target of this agent and the other is focusing on describing its in vitro and in vivo anti-cancer mechanism of action.

Duke University, Durham, NC
An investigator at Duke is examining effects of PG490-88 on graft-vs.-host disease.  This investigator is also acting as a consultant to Pharmagenesis, Inc. for the PG2-2000 development program.

H. Lee Moffitt Cancer Center and Research Institute, University of South Florida
Pharmagenesis, Inc. has one sponsored research agreement in place with the Moffitt Center.  The objective is to evaluate PG2-2000 as a modulator of hematopoiesis.

Shanxi Institute of Chinese Materia Medica, Taiyuan, Shanxi province, PRC
The institute collaborated with Pharmagenesis, Inc. on the development of PG2.

Shanghai Institute of Materia Medica, Shanghai, PRC
They supply Pharmagenesis, Inc. with compounds.

University of North Carolina, Chapel Hill, NC
Pharmagenesis, Inc. has a research collaboration to obtain additional compounds and derivatives from the same TCM plants that produce PG490, PG2 and PG2-2000.

Tri-Service General Hospital, Taipei, Taiwan
There is a collaboration on treating autoimmune diseases with PG27.

Fujian Shanyang Development Co., Ltd. and Fujian Agricultural University, Fujian, PRC
Pharmagenesis, Inc. is collaborating with them for GAP cultivation of TCM plants.

Lijiang Pharmaceutical Co., Ltd.
There is a collaboration on TCM plant biomass collection and crude extraction.


Research Interactions

The majority of earlier Pharmagenesis' collaborators were academic researchers from Taiwan, the PRC and the US.


The previous research collaborators in Taiwan belong to:

Taibei Medical University, Taibei, Taiwan

National Chung Kung University, Tainan, Taiwan

Kaoshiung Medical University, Kaoshiung, Taiwan


Peoples Republic of China

The academicians in the PRC were at:

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

China Institute of Traditional Chinese Medicine, Beijing, China

Peking University Medical School, Beijing, China

United Medical University, Beijing, China


United States

The major investigators in the U.S. were at:

Stanford University Medical School, Stanford, CA

University of North Carolina at Chapel Hill

H. Lee Moffitt Cancer Center and Research Institute, University of South Florida


Pipeline ] Research ] Development ] New Areas ] PG490 Supply ] PG2 ] PG2-2000 ] B50 ] PG36 ] [ Collaborations ] Discovery ] Publications ]

Home ] Management ] R&D ] IP ] Contact ] Site Map ]